BGB A3055
Alternative Names: BGB-A3055Latest Information Update: 14 Oct 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CCR8 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Oct 2025 BGB A3055 is still in phase I trials for Solid tumours (Combination therapy, Late stage disease, Metastatic disease, Second line therapy or greater) in Australia, US, China, France and South Korea (IV)
- 14 Oct 2025 BGB A3055 is still in phase I trials for Solid tumours (Monotherapy, Late stage disease, Metastatic disease, Second line therapy or greater) in Australia, US, China, France and South Korea (IV)
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)